Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PDA-002 in Diabetic Foot Ulcer With Peripheral Arterial Disease
NCT02460081Phase 2Withdrawn
- Sponsor
- Celularity Inc.
- Start
- Jun 2015
- Primary completion
- Jan 2016
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of cenplacel in diabetic foot ulcer (DFU), Peripheral Arterial Disease (PAD), sponsored by Celularity Inc.. Planned start Jun 2015; status: withdrawn.
02
Drugs
cenplacel
03
Conditions
diabetic foot ulcer (DFU)Peripheral Arterial Disease (PAD)
Beyond the preview
Go deeper on NCT02460081.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02460081.